View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Ben Harwood ... (+2)
  • Ben Harwood
  • Pierre FerraguÊ

Tariffs: Autos, Industrials, and Infineon: the baseline & what's next

Evaluating the consequences of tariffs is challenging. As we strengthen our understanding of the tech supply chain, we follow-up on our initial analysis to evaluate the impact on Infineon, as well as the broader Auto and Industrial market. This note follows recent ones we published on Nvidia, Broadcom, Intel/AMD, Semicap & TSMC. Read also our broader notes on tariffs: our baseline thesis for an overall perspective, and our assessment of the macro risk.

 PRESS RELEASE

argenx to Report First Quarter 2025 Financial Results and Business Upd...

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 May 1, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at . A replay of th...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Research Team ACF
  • Research Team ACF

ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
Thomas Vranken
  • Thomas Vranken

argenx FIRST LOOK: Positive CHMP opinion for CIDP

argenx received a positive opinion from the CHMP of the EMA for Vyvgart in treating CIDP in adults with progressive or relapsing disease after prior treatment with corticosteroids or immunoglobulins. The European Commission will now decide on the regulatory submission within 60 days. Vyvgart is the first novel CIDP treatment in over 30 years and could potentially be self-administered. This approval is expected to lead to significant sales in the EU, with EU peak sales estimated at $1.1bn (KBCSe...

 PRESS RELEASE

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa)...

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two months April 28, 2025, 07:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a...

 PRESS RELEASE

Holding(s) in Company

easyJet plc (EZJ) Holding(s) in Company 25-Apr-2025 / 17:30 GMT/BST TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B7KR2P84 Issuer Name EASYJET PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of financial instruments 3. Details of person subject to the notification obligation Name Bank of America Corporation City of registered office (if applicable)   Country of registered office (if applicable) US 4. Details of the shareholder Full name of shar...

Pierre FerraguÊ
  • Pierre FerraguÊ

The Auto and Industrial Semi Recovery is on

Texas Instruments and STM reported overnight and this morning. Please see the link below for our take.

 PRESS RELEASE

Board Changes

easyJet plc (EZJ) Board Changes 23-Apr-2025 / 07:00 GMT/BST 23 April 2025 easyJet plc (‘easyJet’ or the ‘Company’) Board Changes easyJet is pleased to announce that Elyes Mrad will join the Board as a Non-Executive Director and member of the Audit Committee with effect from 1 June 2025. Elyes is currently Executive Vice President, Hertz International, where he oversees the company’s business in EMEA, Latam and Asia Pacific. Before joining Hertz, he held Managing Director roles at Certares, a leading private equity firm focused on the hospitality and travel industry, and Ameri...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

US Tariffs - Broad Tariffs are Highly Unlikely (7pgs)

Following a number of recent events, we discuss in this note what we think is the most likely outcome for the Pharma industry. We show that broad based tariffs on drugs are highly unlikely, that even if it were to happen, the impact of a 20% tariff is

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch